Despite recent therapeutic advances, the prognosis of patients with KRAS mutant metastatic colorectal cancer (CRC) remains dismal with an average median overall survival (OS) of approximately 13.5 months 1. The gene discussed is KRAS; the disease is colorectal carcinoma.